These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 259497)

  • 41. Small molecule probes of glyoxalase I and glyoxalase II.
    Barnard JF; Vander Jagt DL; Honek JF
    Biochim Biophys Acta; 1994 Sep; 1208(1):127-35. PubMed ID: 8086426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glyoxalase I from human erythrocytes.
    Mannervik B; Aronsson AC; Tibbelin G
    Methods Enzymol; 1982; 90 Pt E():535-41. PubMed ID: 7154966
    [No Abstract]   [Full Text] [Related]  

  • 43. Novel glyoxalase-I inhibitors possessing a "zinc-binding feature" as potential anticancer agents.
    Al-Balas QA; Hassan MA; Al-Shar'i NA; Mhaidat NM; Almaaytah AM; Al-Mahasneh FM; Isawi IH
    Drug Des Devel Ther; 2016; 10():2623-9. PubMed ID: 27574401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glyoxalase I inhibitors in cancer chemotherapy.
    Creighton DJ; Zheng ZB; Holewinski R; Hamilton DS; Eiseman JL
    Biochem Soc Trans; 2003 Dec; 31(Pt 6):1378-82. PubMed ID: 14641067
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I.
    More SS; Vince R
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6039-42. PubMed ID: 16997560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of glyoxalase I: design, synthesis, inhibitory characteristics and biological evaluation.
    Allen RE; Lo TW; Thornalley PJ
    Biochem Soc Trans; 1993 May; 21(2):535-40. PubMed ID: 8359527
    [No Abstract]   [Full Text] [Related]  

  • 47. The influence of porphyrogenic drugs on the glyoxalase enzymes.
    Van Brummelen R; Myburgh S; Bissbort SH
    Res Commun Chem Pathol Pharmacol; 1993 Dec; 82(3):339-49. PubMed ID: 8122034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trapping of reactive intermediates in enzymology. Exogenous flavin reduction during catalytic turnover of substrate by glyoxalase I.
    Douglas KT; Quilter AJ; Shinkai S; Ueda K
    Biochim Biophys Acta; 1985 May; 829(1):119-26. PubMed ID: 3888272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Purification and kinetic study of glyoxalase-I from rat liver, erythrocytes, brain and kidney.
    Han LP; Davison LM; Vander Jagt DL
    Biochim Biophys Acta; 1976 Sep; 445(2):486-99. PubMed ID: 953039
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemical modification of tyrosine residues in glyoxalase I from yeast and human erythrocytes.
    Carrington SJ; Fetherbe D; Douglas KT
    Int J Biochem; 1989; 21(8):901-8. PubMed ID: 2684702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Computational and experimental exploration of the structure-activity relationships of flavonoids as potent glyoxalase-I inhibitors.
    Al-Balas QA; Hassan MA; Al-Shar'i NA; El-Elimat T; Almaaytah AM
    Drug Dev Res; 2018 Mar; 79(2):58-69. PubMed ID: 29285772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, and binding studies of bidentate Zn-chelating peptidic inhibitors of glyoxalase-I.
    More SS; Vince R
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3793-7. PubMed ID: 17513107
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel bivalent inhibitors with sub-nanomolar affinities towards human glyoxalase I.
    Sang Y; Shi Q; Mo M; Ni C; Li Z; Liu B; Deng Q; Creighton DJ; Zheng ZB
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4724-4727. PubMed ID: 26320622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of pharmacophore modeling and 3D-QSAR analysis of potential glyoxalase-I inhibitors as anticancer agents.
    Al-Sha'er MA; Al-Balas QA; Hassan MA; Al Jabal GA; Almaaytah AM
    Comput Biol Chem; 2019 Jun; 80():102-110. PubMed ID: 30947068
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluorescence and nuclear relaxation enhancement studies of the binding of glutathione derivatives to manganese-reconstituted glyoxalase I from human erythrocytes. A model for the catalytic mechanism of the enzyme involving a hydrated metal ion.
    Sellin S; Eriksson LE; Mannervik B
    Biochemistry; 1982 Sep; 21(20):4850-7. PubMed ID: 7138835
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I.
    Liu M; Yuan M; Li Z; Cheng YK; Luo HB; Hu X
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4243-7. PubMed ID: 21689932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reaction of COTC with glutathione: structure of the putative glyoxalase I inhibitor.
    Huntley CF; Hamilton DS; Creighton DJ; Ganem B
    Org Lett; 2000 Oct; 2(20):3143-4. PubMed ID: 11009366
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Purification and properties of glyoxalase I from sheep liver.
    Uotila L; Koivusalo M
    Eur J Biochem; 1975 Apr; 52(3):493-503. PubMed ID: 19241
    [No Abstract]   [Full Text] [Related]  

  • 59. Glyoxalase I and glyoxalase II from Aloe vera: purification, characterization and comparison with animal glyoxalases.
    Norton SJ; Talesa V; Yuan WJ; Principato GB
    Biochem Int; 1990 Nov; 22(3):411-8. PubMed ID: 2076100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutagenesis of residue 157 in the active site of human glyoxalase I.
    Ridderström M; Cameron AD; Jones TA; Mannervik B
    Biochem J; 1997 Nov; 328 ( Pt 1)(Pt 1):231-5. PubMed ID: 9359858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.